Transcription of Public Assessment Report Decentralised Procedure - …
{{id}} {{{paragraph}}}
Example: barber
Public Assessment Report Decentralised Procedure - …
PAR Tephine/ buprenorphine 200 microgam and 400 microgram Sublingual Tablets UK/H/1943-5/001-2/DC 1 Public Assessment Report Decentralised Procedure Tephine 200 microgram and 400 microgram Sublingual Tablets buprenorphine 200 microgram and 400 microgram Sublingual Tablets UK/H/1943/001-2/DC UK/H/1944/001-2/DC UK/H/1945/001-2/DC UK licence numbers: PL 04416/0956-957, 0958-959 & 1169-70 Sandoz Limited PAR Tephine/ buprenorphine 200 microgam and 400 microgram Sublingual Tablets UK/H/1943-5/001-2/DC 2 LAY SUMMARY On 2nd September 2011, the MHRA granted Sandoz Limited Marketing Authorisations (licences) for the medicinal products buprenorphine 200 microgram and 400 microgram Sublingual Tablets. The products are licensed under the following trade names but will be referred to by the generic names, buprenorphine 200 microgram and 400 microgram Sublingual Tablets, in the remainder of this Report : PL 04416/0956-57 Tephine 200 microgram and 400 microgram Sublingual Tablets PL 04416/0958-59 buprenorphine 200 microgram and 400 microgram Sublingual Tablets PL 04416/1169-70 buprenorphine 200 microgram and 400 microgram Sublingual Tablets These are prescription-only medicines (POM).
PAR Tephine/Buprenorphine 200 microgam and 400 microgram Sublingual Tablets UK/H/1943-5/001-2/DC 2 LAY SUMMARY On 2nd September 2011, the MHRA granted Sandoz Limited Marketing Authorisations (licences) for the medicinal products Buprenorphine 200 microgram and 400 microgram
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: